GB2316004B - Novel formulations for transdermal delivery of pergolide - Google Patents

Novel formulations for transdermal delivery of pergolide

Info

Publication number
GB2316004B
GB2316004B GB9724267A GB9724267A GB2316004B GB 2316004 B GB2316004 B GB 2316004B GB 9724267 A GB9724267 A GB 9724267A GB 9724267 A GB9724267 A GB 9724267A GB 2316004 B GB2316004 B GB 2316004B
Authority
GB
United Kingdom
Prior art keywords
pergolide
composition
transdermal delivery
novel formulations
enhancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
GB9724267A
Other languages
English (en)
Other versions
GB2316004A (en
GB9724267D0 (en
Inventor
Su Ii Yum
Melinda K Nelson
Patricia S Campbell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of GB9724267D0 publication Critical patent/GB9724267D0/en
Publication of GB2316004A publication Critical patent/GB2316004A/en
Application granted granted Critical
Publication of GB2316004B publication Critical patent/GB2316004B/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
GB9724267A 1995-06-07 1996-06-07 Novel formulations for transdermal delivery of pergolide Expired - Lifetime GB2316004B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/473,631 US6572879B1 (en) 1995-06-07 1995-06-07 Formulations for transdermal delivery of pergolide
PCT/US1996/009692 WO1996040139A1 (en) 1995-06-07 1996-06-07 Novel formulations for transdermal delivery of pergolide

Publications (3)

Publication Number Publication Date
GB9724267D0 GB9724267D0 (en) 1998-01-14
GB2316004A GB2316004A (en) 1998-02-18
GB2316004B true GB2316004B (en) 1999-08-04

Family

ID=23880356

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9724267A Expired - Lifetime GB2316004B (en) 1995-06-07 1996-06-07 Novel formulations for transdermal delivery of pergolide

Country Status (12)

Country Link
US (3) US6572879B1 (ja)
EP (2) EP0831827B1 (ja)
JP (2) JPH11507361A (ja)
AT (1) ATE361073T1 (ja)
AU (1) AU6476496A (ja)
CA (1) CA2221263A1 (ja)
DE (2) DE69637061T2 (ja)
DK (1) DK0831827T3 (ja)
ES (1) ES2285704T3 (ja)
GB (1) GB2316004B (ja)
PT (1) PT831827E (ja)
WO (1) WO1996040139A1 (ja)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572879B1 (en) * 1995-06-07 2003-06-03 Alza Corporation Formulations for transdermal delivery of pergolide
US6623752B1 (en) 1996-07-02 2003-09-23 Hexal Ag Patch for transdermal application for pergolid
DE19626621A1 (de) * 1996-07-02 1998-01-08 Hexal Ag Pflaster zur transdermalen Anwendung von Pergolid
DE69718037T2 (de) * 1996-10-24 2003-07-10 Alza Corp Penetrationsfördernde substanzen für die transdermale verabreichung von wirkstoffen, vorrichtungen und verfahren zur herstellung
DE19821788C1 (de) * 1998-05-15 1999-12-02 Sanol Arznei Schwarz Gmbh Transdermales Therapeutisches System (TTS) Pergolid enthaltend
NZ513441A (en) † 1999-02-08 2004-01-30 Alza Corp Stable non-aqueous single phase viscous drug delivery vehicles comprising a polymer a solvent and a surfactant
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
DE10341317B4 (de) * 2003-09-03 2008-10-23 Axxonis Pharma Ag Transdermales therapeutisches System (TTS) zur Verabreichung von Ergolinverbindungen ausgenommen Pergolid
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
GB0026137D0 (en) * 2000-10-25 2000-12-13 Euro Celtique Sa Transdermal dosage form
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10110953A1 (de) * 2001-03-07 2002-09-19 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Verabreichung von partiellen Dopamin-D2-Agonisten
CA2443128A1 (en) * 2001-03-30 2002-10-10 Debra A. Martin Transdermal delivery of pergolide
FR2823999B1 (fr) * 2001-04-27 2003-06-27 Commissariat Energie Atomique Dispositif miniature de separation et d'isolement d'objets biologiques et utilisations
ATE547095T1 (de) 2001-05-11 2012-03-15 Isis Pharmaceuticals Inc Antisense-permeationsverstärker
US20040120995A1 (en) * 2002-04-01 2004-06-24 Martin Debra A Transdermal delivery of pergolide
EA200401565A1 (ru) * 2002-05-24 2005-04-28 Неофарм, Инк. Способ получения кардиолипина или аналога кардиолипина (варианты), способ получения липосомы и композиция кардиолипина для лечения заболеваний (варианты)
EP1513853A2 (en) * 2002-05-24 2005-03-16 Neopharm, Inc. Cardiolipin compositions, methods of preparation and use
JP4213432B2 (ja) * 2002-08-28 2009-01-21 久光製薬株式会社 貼付剤
JP4792193B2 (ja) * 2002-08-28 2011-10-12 久光製薬株式会社 貼付剤
US20050277611A1 (en) * 2002-10-16 2005-12-15 Neopharm, Inc. Cationic cardiolipin analoges and its use thereof
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
DE602004026173D1 (de) 2003-04-29 2010-05-06 Gen Hospital Corp Verfahren und vorrichtungen für die verzögerte freisetzung von mehreren arzneimitteln
TW200514582A (en) * 2003-10-31 2005-05-01 Hisamitsu Pharmaceutical Co Transdermal preparation and method for reducing side effect in pergolide therapy
US20050191338A1 (en) * 2004-01-30 2005-09-01 Lifeng Kang Transdermal drug delivery composition comprising a small molecule gel and process for the preparation thereof
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
DE102005050431A1 (de) * 2005-10-21 2007-04-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreicherung lipophiler und/oder wenig hautpermeabler Wirkstoffe
US7704977B2 (en) 2006-04-07 2010-04-27 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
DE602007009377D1 (de) 2006-05-30 2010-11-04 Intarcia Therapeutics Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
CA2654566A1 (en) * 2006-06-09 2007-12-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7682356B2 (en) 2006-08-09 2010-03-23 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies for use therein
SA08290041B1 (ar) 2007-02-01 2012-06-05 فيرينج انترناشونال سنتر اس آيه أدوية من أجل معالجة بطانة الرحم
GB2450533A (en) * 2007-06-29 2008-12-31 Ferring Int Ct Sa Treatment and prevention of endometriosis using dopamine agonists.
JP5351884B2 (ja) 2007-04-23 2013-11-27 インターシア セラピューティクス，インコーポレイティド インスリン分泌促進性ペプチドの懸濁製剤及び使用
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
JP2011519928A (ja) 2008-05-07 2011-07-14 メリオン・リサーチ・Ｉｉｉ・リミテッド ペプチドの組成物及びその調製方法
US20130274352A1 (en) * 2009-04-14 2013-10-17 The Regents Of The University Of California Oral Drug Devices and Drug Formulations
HUE035862T2 (en) 2009-09-28 2018-05-28 Intarcia Therapeutics Inc Rapid development and / or completion of substantially steady-state drug delivery
US9089484B2 (en) 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
AU2012204213A1 (en) 2011-01-07 2013-06-13 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9072682B2 (en) 2012-12-31 2015-07-07 Mylan Inc. Transdermal dosage form for low-melting point active agent
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP3250191B1 (en) 2015-01-29 2024-01-17 Novo Nordisk A/S Tablets comprising glp-1 agonist and enteric coating
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
US20190374534A1 (en) 2018-06-08 2019-12-12 Boehringer Ingelheim Vetmedica Gmbh Liquid pharmaceutical compositions comprising pergolide

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000746A1 (en) * 1989-07-12 1991-01-24 Cygnus Research Corporation Transdermal administration of lisuride
EP0458640A2 (en) * 1990-05-25 1991-11-27 Eli Lilly And Company Use of ergoline derivatives for the treatment of diseases associated with bone demineralization
DE4240798A1 (en) * 1991-12-03 1993-06-09 Poli Industria Chimica S.P.A., Mailand/Milano, It Neuro-protective agents preventing nerve damage - contain ergot derivs. e.g. clavine lysergic acid amide or 8-alpha-amino:ergoline derivs.

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3797494A (en) 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3731683A (en) 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US4144317A (en) 1975-05-30 1979-03-13 Alza Corporation Device consisting of copolymer having acetoxy groups for delivering drugs
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
JPH0240647B2 (ja) * 1978-02-08 1990-09-12 Lilly Co Eli Purorakuchinbunpyokuseizai
JPH0240044B2 (ja) * 1978-02-08 1990-09-10 Lilly Co Eli Paakinsonshokogunchiryozai
US4166182A (en) * 1978-02-08 1979-08-28 Eli Lilly And Company 6-n-propyl-8-methoxymethyl or methylmercaptomethylergolines and related compounds
US4286592A (en) 1980-02-04 1981-09-01 Alza Corporation Therapeutic system for administering drugs to the skin
US4314557A (en) 1980-05-19 1982-02-09 Alza Corporation Dissolution controlled active agent dispenser
US4379454A (en) 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4849226A (en) 1981-06-29 1989-07-18 Alza Corporation Method for increasing oxygen supply by administering vasodilator
US4435180A (en) 1982-05-25 1984-03-06 Alza Corporation Elastomeric active agent delivery system and method of use
US4559222A (en) 1983-05-04 1985-12-17 Alza Corporation Matrix composition for transdermal therapeutic system
US4704282A (en) 1984-06-29 1987-11-03 Alza Corporation Transdermal therapeutic system having improved delivery characteristics
US4588580B2 (en) 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
US4568343A (en) 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4573995A (en) 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
US4675322A (en) * 1984-12-10 1987-06-23 Eli Lilly And Company 1-Substituted-6-n-propyl-8β-methylthio-methylergolines
US4645502A (en) 1985-05-03 1987-02-24 Alza Corporation Transdermal delivery of highly ionized fat insoluble drugs
US4782152A (en) * 1985-08-16 1988-11-01 Eli Lilly And Company Decyanation of pergolide intermediate
US4935429A (en) 1985-10-25 1990-06-19 Dackis Charles A Method of treating psychostimulant addiction
US4908027A (en) 1986-09-12 1990-03-13 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US4746515A (en) 1987-02-26 1988-05-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolaurate
US4788062A (en) 1987-02-26 1988-11-29 Alza Corporation Transdermal administration of progesterone, estradiol esters, and mixtures thereof
US4816258A (en) 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
US4800204A (en) 1987-05-07 1989-01-24 Mueller Peter S Method of controlling tobacco use
US4764379A (en) * 1987-08-24 1988-08-16 Alza Corporation Transdermal drug delivery device with dual permeation enhancers
US4943435A (en) 1987-10-05 1990-07-24 Pharmetrix Corporation Prolonged activity nicotine patch
US4797405A (en) * 1987-10-26 1989-01-10 Eli Lilly And Company Stabilized pergolide compositions
US5446070A (en) * 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US4814168A (en) * 1988-03-04 1989-03-21 Noven Pharmaceuticals, Inc. Transdermal multipolymer drug delivery system
US5378730A (en) * 1988-06-09 1995-01-03 Alza Corporation Permeation enhancer comprising ethanol and monoglycerides
US5004610A (en) 1988-06-14 1991-04-02 Alza Corporation Subsaturated nicotine transdermal therapeutic system
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
US5229129A (en) 1989-07-12 1993-07-20 Cygnus Therapeutic Systems Transdermal administration of lisuride
US5114948A (en) * 1989-10-19 1992-05-19 Eli Lilly And Company Stabilized pergolide compositions
US5314694A (en) 1990-10-29 1994-05-24 Alza Corporation Transdermal formulations, methods and devices
JP3255717B2 (ja) * 1991-08-08 2002-02-12 積水化学工業株式会社 経皮吸収製剤
CA2090598A1 (en) 1992-03-04 1993-09-05 Kirti Himatlal Valia Titratable transdermal patch system and method for administration of therapeutic substances
JPH05271658A (ja) * 1992-03-27 1993-10-19 Chisso Corp 反強誘電性液晶組成物
AU677206B2 (en) * 1992-06-11 1997-04-17 Theratech, Inc. The use of glycerin in moderating transdermal drug delivery
US5607691A (en) 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
ATE149349T1 (de) * 1993-06-25 1997-03-15 Alza Corp Einarbeitung eines poly-n-vinylamids in ein transdermales system
ATE246909T1 (de) * 1994-03-07 2003-08-15 Theratech Inc Medikament enthaltende, adhesive, zusammenbaubare,transdermale abgabevorrichtung
US6572879B1 (en) * 1995-06-07 2003-06-03 Alza Corporation Formulations for transdermal delivery of pergolide

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000746A1 (en) * 1989-07-12 1991-01-24 Cygnus Research Corporation Transdermal administration of lisuride
EP0458640A2 (en) * 1990-05-25 1991-11-27 Eli Lilly And Company Use of ergoline derivatives for the treatment of diseases associated with bone demineralization
DE4240798A1 (en) * 1991-12-03 1993-06-09 Poli Industria Chimica S.P.A., Mailand/Milano, It Neuro-protective agents preventing nerve damage - contain ergot derivs. e.g. clavine lysergic acid amide or 8-alpha-amino:ergoline derivs.

Also Published As

Publication number Publication date
DE69637061T2 (de) 2008-01-10
JPH11507361A (ja) 1999-06-29
EP0831827B1 (en) 2007-05-02
DK0831827T3 (da) 2007-09-10
AU6476496A (en) 1996-12-30
GB2316004A (en) 1998-02-18
GB9724267D0 (en) 1998-01-14
EP0831827A1 (en) 1998-04-01
ATE361073T1 (de) 2007-05-15
DE19681435T1 (de) 1998-07-23
US6572879B1 (en) 2003-06-03
US20040209909A1 (en) 2004-10-21
ES2285704T3 (es) 2007-11-16
PT831827E (pt) 2007-07-20
JP2007238636A (ja) 2007-09-20
EP1428527A1 (en) 2004-06-16
DE69637061D1 (de) 2007-06-14
WO1996040139A1 (en) 1996-12-19
CA2221263A1 (en) 1996-12-19
MX9709872A (es) 1998-08-30
US6001390A (en) 1999-12-14

Similar Documents

Publication Publication Date Title
GB2316004B (en) Novel formulations for transdermal delivery of pergolide
CY2503B1 (en) Novel formulations for the transdermal administration of fluoxetine acetate and fluoxetine maleate.
MX9709162A (es) Composiciones mejoradas de la permeacion en la piel que usan lactilatos de acilo.
EP0429039A3 (en) Use of an opiate antagonist for the preparation of a pharmaceutical composition to be transdermally administered, and device for transdermal delivery
EP1243267A3 (en) Amoxycillin and clavulanate containing pharmaceutical formulation
ZA946698B (en) Medical device for the administration of active ingredients or drugs at very low doses particularly homeopathic drugs
EP0740650A4 (en) CO-MEDICINAL PRODUCTS USED AS A REGULATED MEDICINE DELIVERY PROCESS
AU7396294A (en) Incorporating poly-n-vinyl amide in a transdermal system
CA2132865A1 (en) Transdermal administration of oxybutynin
WO1998017315A3 (en) Permeation enhancers for transdermal drug delivery compositions, devices, and methods
AU681452B2 (en) Pernasal composition and pernasal preparation containing thesame
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
MY130098A (en) Local drug delivery film for periodontal treatment
DE69737723D1 (de) Behalter zur iontophoretischen verabreichung von medikamenten mit inerten material-bestandteilen
WO2000048445A3 (de) Pharmazeutische zusammensetzung enthaltend desoxypeganin zur behandlung der nikotinabhängigkeit
EP1023901A4 (en) MEDICINES FOR HEPATITIS C AND THE USE THEREOF
AU3278800A (en) Pharmaceutical composition containing desoxypeganine for the treatment of drug dependence
HK1036594A1 (en) Formulations for the transdermal administration offenoldopam.
AU2907800A (en) Pharmaceutical composition containing desoxypeganine for the treatment of alcoholism
EP0811385A3 (en) Conjugate of a factor specifically recognizing interleukin-2 receptor with ribonuclease
ZA811503B (en) Substituted cyclo-hebtenes, their preparation, and therapetic agents containing these compounds

Legal Events

Date Code Title Description
727 Application made for amendment of specification (sect. 27/1977)
727A Application for amendment of specification now open to opposition (sect. 27/1977)
727H Specification amended (sect. 27/1977)
PE20 Patent expired after termination of 20 years

Expiry date: 20160606